Titan Pharmaceuticals, Inc.
TTNP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $60 | $1,526 |
| % Growth | -100% | -98.3% | -96.1% | – |
| Cost of Goods Sold | $5 | $0 | $196 | $199 |
| Gross Profit | -$5 | $1 | -$136 | $1,327 |
| % Margin | – | 100% | -226.7% | 87% |
| R&D Expenses | $0 | $1,913 | $4,758 | $5,692 |
| G&A Expenses | $4,557 | $5,548 | $6,034 | $4,989 |
| SG&A Expenses | $4,557 | $5,548 | $6,034 | $4,989 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$183 | -$497 | -$84 |
| Operating Expenses | $4,557 | $7,278 | $10,295 | $10,681 |
| Operating Income | -$4,557 | -$7,277 | -$10,235 | -$9,354 |
| % Margin | – | -727,700% | -17,058.3% | -613% |
| Other Income/Exp. Net | -$149 | $1,708 | $29 | $578 |
| Pre-Tax Income | -$4,706 | -$5,569 | -$10,206 | -$8,776 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,706 | -$5,569 | -$10,177 | -$8,114 |
| % Margin | – | -556,900% | -16,961.7% | -531.7% |
| EPS | -5.23 | -7.41 | -15.15 | -4.06 |
| % Growth | 29.4% | 51.1% | -273.2% | – |
| EPS Diluted | -5.23 | -7.41 | -15.15 | -4.06 |
| Weighted Avg Shares Out | 899 | 752 | 672 | 1,998 |
| Weighted Avg Shares Out Dil | 899 | 752 | 672 | 1,998 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $5 | $53 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $112 | $196 | $221 |
| EBITDA | -$4,701 | -$7,165 | -$10,039 | -$9,133 |
| % Margin | – | -716,500% | -16,731.7% | -598.5% |